An IL-1 blocker for gout flares when the kidneys tie your hands

Design

Double-blind, double-dummy, multicentre randomised feasibility trial

Population

21 patients with gout and CKD (eGFR under 60); mean age 72, mean eGFR 44

Primary outcome

Feasibility of a definitive trial (recruitment, retention, assessments)

Effect

Mean pain reduction 46.8 mm (of 100) by day 7; anakinra appeared faster (unconfirmed)

Treating a gout flare in chronic kidney disease is hard: NSAIDs are contraindicated, colchicine needs dose reduction, and steroids unsettle glycaemia. ASGARD, a UK double-blind feasibility trial, randomised patients with gout and an eGFR under 60 to subcutaneous anakinra (an interleukin-1 receptor antagonist) or intramuscular methylprednisolone.

The trial under-recruited (21 of a planned 32 randomised; mean age 72, mean eGFR 44) and so did not meet its overall feasibility target, though procedural measures were largely met. Mean pain fell 46.8 mm on a 100 mm scale by day 7, and anakinra appeared to act faster, a signal the authors stress needs a larger trial to confirm.

The practical interest is the option itself: IL-1 blockade is a mechanistically attractive, steroid- and NSAID-sparing choice for gout flares in CKD. This study does not establish efficacy, but it keeps a useful alternative on the table and flags the real-world barrier of getting treatment to patients quickly during a flare.

• Gout flares in CKD are hard to treat: NSAIDs contraindicated, colchicine limited, steroids problematic.
• ASGARD compared anakinra with intramuscular methylprednisolone in CKD (eGFR under 60).
• It under-recruited (21 patients) and did not meet its overall feasibility target.
• Pain fell 46.8 mm by day 7, with anakinra appearing faster, unconfirmed.
• Consider IL-1 blockade as a steroid- and NSAID-sparing option, pending better evidence.

Why it matters

It addresses a genuinely awkward clinical problem, the gout flare in a patient whose kidneys rule out the usual drugs.

Don't overread it

Small, under-recruited feasibility trial; it does not establish that anakinra is superior, only that a definitive trial is worth pursuing.

The statistics, in plain English

A feasibility trial tests whether a definitive study can be run, not whether a drug works; with only 21 patients, the faster-pain-relief signal is hypothesis-generating, not proof.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.